studies

non squamous - mNSCLC - L1 - all population, atezolizumab plus carboplatin plus nab-paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-130 (all population), 2019 (REV) 1.25 [1.01; 1.54] 1.25[1.01; 1.54]IMpower-130 (all population), 2019 (REV)10%723NAnot evaluable progression or deaths (PFS)detailed resultsIMpower-130 (all population), 2019 (REV) 1.54 [1.29; 1.84] 1.54[1.29; 1.84]IMpower-130 (all population), 2019 (REV)10%723NAnot evaluable AE (any grade)detailed resultsIMpower-130 (all population), 2019 (REV) 0.49 [0.07; 3.49] 0.49[0.07; 3.49]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.58 [0.41; 0.84] 0.58[0.41; 0.84]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable AE leading to death (grade 5)detailed resultsIMpower-130 (all population), 2019 (REV) 1.06 [0.53; 2.12] 1.06[0.53; 2.12]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-130 (all population), 2019 (REV) 0.78 [0.54; 1.14] 0.78[0.54; 1.14]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable SAE (any grade)detailed resultsIMpower-130 (all population), 2019 (REV) 0.59 [0.43; 0.82] 0.59[0.43; 0.82]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable STRAE (any grade)detailed resultsIMpower-130 (all population), 2019 (REV) 0.48 [0.31; 0.74] 0.48[0.31; 0.74]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable TRAE (any grade)detailed resultsIMpower-130 (all population), 2019 (REV) 0.50 [0.25; 0.99] 0.50[0.25; 0.99]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.56 [0.40; 0.78] 0.56[0.40; 0.78]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-130 (all population), 2019 (REV) 0.25 [0.03; 2.02] 0.25[0.03; 2.02]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19] 2.04[0.04; 103.19]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.62 [0.42; 0.90] 0.62[0.42; 0.90]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.68 [0.18; 2.52] 0.68[0.18; 2.52]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.17 [0.34; 4.03] 1.17[0.34; 4.03]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.97 [0.47; 2.03] 0.97[0.47; 2.03]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19] 2.04[0.04; 103.19]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.98 [0.51; 1.90] 0.98[0.51; 1.90]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.62 [0.20; 1.93] 0.62[0.20; 1.93]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.82 [0.58; 1.16] 0.82[0.58; 1.16]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.66 [0.36; 1.21] 0.66[0.36; 1.21]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.68 [0.18; 2.52] 0.68[0.18; 2.52]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.81 [0.16; 4.23] 0.81[0.16; 4.23]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Agranulocytosis (AE grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 4.09 [0.14; 122.39] 4.09[0.14; 122.39]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19] 2.04[0.04; 103.19]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.68 [0.47; 0.97] 0.68[0.47; 0.97]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.13 [0.01; 2.20] 0.13[0.01; 2.20]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.63 [0.23; 1.74] 0.63[0.23; 1.74]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.25 [0.03; 2.02] 0.25[0.03; 2.02]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32] 0.51[0.02; 11.32]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.34 [0.02; 6.78] 0.34[0.02; 6.78]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.20 [0.01; 3.72] 0.20[0.01; 3.72]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Cough AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.34 [0.02; 6.78] 0.34[0.02; 6.78]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.34; 3.02] 1.02[0.34; 3.02]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Diabetes mellitus AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32] 0.51[0.02; 11.32]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.15 [0.59; 2.26] 1.15[0.59; 2.26]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Dizziness AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.13; 32.81] 2.04[0.13; 32.81]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Dry skin AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 4.09 [0.14; 122.39] 4.09[0.14; 122.39]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19] 2.04[0.04; 103.19]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.18 [0.04; 0.76] 0.18[0.04; 0.76]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.13; 32.81] 2.04[0.13; 32.81]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.78 [0.41; 1.48] 0.78[0.41; 1.48]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.12 [0.41; 3.05] 1.12[0.41; 3.05]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Gastritis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32] 0.51[0.02; 11.32]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.68 [0.14; 3.38] 0.68[0.14; 3.38]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.04 [0.13; 32.81] 2.04[0.13; 32.81]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32] 0.51[0.02; 11.32]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.25; 4.11] 1.02[0.25; 4.11]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.37 [0.38; 4.89] 1.37[0.38; 4.89]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.64 [0.27; 1.52] 0.64[0.27; 1.52]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.63 [0.23; 1.74] 0.63[0.23; 1.74]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.81 [0.57; 1.14] 0.81[0.57; 1.14]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Pancytopenia (AE grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 2.05 [0.29; 14.63] 2.05[0.29; 14.63]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32] 0.51[0.02; 11.32]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.36 [0.23; 8.21] 1.36[0.23; 8.21]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.36 [0.23; 8.21] 1.36[0.23; 8.21]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.25; 4.11] 1.02[0.25; 4.11]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.72 [0.34; 1.50] 0.72[0.34; 1.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 4.09 [0.14; 122.39] 4.09[0.14; 122.39]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Rash AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.09; 11.30] 1.02[0.09; 11.30]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50] 1.02[0.03; 30.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.14 [0.01; 2.54] 0.14[0.01; 2.54]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 4.10 [0.37; 45.50] 4.10[0.37; 45.50]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.67 [0.37; 1.21] 0.67[0.37; 1.21]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 0.78 [0.27; 2.21] 0.78[0.27; 2.21]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 (REV) 1.02 [0.09; 11.30] 1.02[0.09; 11.30]IMpower-130 (all population), 2019 (REV)10%705NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-04 05:50 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 165 - treatments: 865

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons